Mitosene-DNA adducts. Characterization of two major DNA monoadducts formed by 1,10-bis(acetoxy)-7-methoxymitosene upon reductive activation by Maliepaard, Marc et al.
Mitosene-DNA Adducts. Characterization of Two Major DNA Monoadducts
Formed by 1,10-Bis(acetoxy)-7-methoxymitosene upon Reductive Activation†
Marc Maliepaard,*,‡ Nico J. de Mol,‡ Maria Tomasz,§ Dario Gargiulo,§ Lambert H. M. Janssen,‡
John P. M. van Duynhoven,| Ewoud J. J. van Velzen,| Willem Verboom,| and David N. Reinhoudt|
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Utrecht UniVersity, P.O. Box 80082, 3508 TB Utrecht,
The Netherlands, Department of Chemistry, Hunter College, City UniVersity of New York, New York, New York 10021,
and Laboratory of Organic Chemistry, Faculty of Chemical Technology, UniVersity of Twente, P.O. Box 217, 7500
AE Enschede, The Netherlands
ReceiVed January 13, 1997; ReVised Manuscript ReceiVed April 16, 1997X
ABSTRACT: Reductive activation of racemic 1,10-bis(acetoxy)-7-methoxymitosene WV15 in the presence
of DNA, followed by enzymatic digestion and HPLC analysis, revealed the formation of various DNA
adducts. Reduction is a necessary event for adduct formation to occur. This reductive activation was
performed under hypoxic conditions in various ways: (1) chemically, using a 2-fold excess of sodium
dithionite (Na2S2O4), (2) enzymatically using NADH-cytochrome c reductase, (3) electrochemically on a
mercury pool working electrode, and (4) catalytically, using a H2/PtO2 system. Five different mitosene-
DNA adducts were detected. These adducts were also present when poly(dG-dC) was used instead of
DNA, but were absent with poly(dA-dT). All were shown to be adducts of guanine. Reduction of 1,-
10-dihydroxymitosene WV14 in the presence of DNA did not result in detectable adduct formation,
demonstrating the importance of good leaving groups for efficient adduct formation by these mitosenes.
Finally, two of the adducts were isolated and their structures elucidated, using mass spectrometry, 1H
NMR and circular dichroism (CD). The structures were assigned as the diastereoisomers N2-(1′′-n-
hydroxymitosen-10′′-yl), 2′-deoxyguanosine (n ) R or â). These type of adducts, in which the mitosene
C-10 is covalently bonded to the N-2 of a guanosylic group, are different from the well-known mitomycin
C 2′-deoxyguanosine monoadducts, that is linked via the mitomycin C C-1 position, demonstrating that
the order of reactivity of the C-1 and C-10 in these mitosenes is reversed, as compared to mitomycin C.
The 7-methoxy substituent of WV15 is a likely factor causing this switch. Evidence is presented that the
7-substituent of mitosenes also influences their DNA alkylation site. Adducts 4 and 5 represent the first
isolated and structurally characterized covalent adducts of DNA and a synthetic mitosene.
Mitosenes (basic structure 1) are derived from the clini-
cally significant cytostatic agent mitomycin C (Chart 1),
which is used in the treatment of solid tumors in the breast,
lung, and the gastrointestinal tract (Remers & Dorr, 1988).
Mitomycin C requires reductive activation to exert its
antitumor activity (Doroshow, 1992). Several types of
reduction, e.g., chemical (Iyer & Szybalski, 1964; Tomasz
et al., 1986, 1988a; Hong & Kohn, 1991; Schiltz & Kohn
1992), electrochemical (Andrews et al., 1986; Kohn et al.,
1987; Maliepaard et al., 1993), and enzymatic (Tomasz et
al., 1981; Keyes et al, 1984; Pan et al., 1984, 1986; Gustafson
& Pritsos, 1992; Siegel et al., 1992; Prakash et al., 1993;
Hodnick & Sartorelli, 1993) have been used to activate
mitomycin C in Vitro. The activation mechanism of mito-
mycin C (Scheme 1) has been studied extensively and has
been shown to proceed via reduced mitosene intermediates
(Rao et al., 1977; Danishefski & Ciufolini, 1984; Danishefski
& Egbertson, 1986; Peterson & Fisher, 1986, Andrews et
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1 Abbreviations: AcN, acetonitrile; CD, circular dichroism; CI,
chemical ionization; dG, deoxyguanosine; EDTA, ethylenediaminetet-
raacetic acid; EI, electron impact; MeOH, methanol; NH4Ac, am-
monium acetate; SVD, snake venom diesterase; v/v, volume to volume
ratio.
2 The original definition of the trivial name mitosene included as
invariant the C-10 carbamoyloxy substituent in structure 1 (Webb et
al., 1962a). In this article, mitosene is redefined as structure 1, i.e., R1
is a variable substituent of mitosene.
Chart 1
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al., 1986; Hoey et al., 1988; Schiltz & Kohn, 1993a,b). The
C-1 of mitomycin C is the most reactive site following
reductive activation [e.g., Remers and Dorr (1988) and Kohn
and Hong (1990)]. Activation of the C-10 site of mitomycin
C has only been detected after opening of the C-1 aziridine
group [e.g., Iyengar et al. (1990) and Kohn and Hong
(1990)]. In the absence of external nucleophiles, reductively
activated mitomycin C preferentially acts as a trapping agent
for electrophiles, whereas in the presence of nucleophiles
(e.g., DNA) nucleophilic substitution reactions can take place
at the C-1 and C-10 site of mitomycin C (Schiltz and Kohn,
1993b). Thus, following reductive activation, mitomycin C
is capable of binding to the N-2 of a 2′-deoxyguanosyl
residue in DNA via the C-1 site (Tomasz et al., 1986, 1988b;
Kumar et al., 1992), or via both the C-1 and C-10 sites
(Tomasz et al., 1987). In the latter case, DNA inter- and
intrastrand cross-links can be formed (Bizanek et al., 1992)
(Scheme 2). Interstrand cross-links can prevent (tumor) cell
division and are therefore considered to be the ultimate cause
for antitumor activity of mitomycin C (Zwelling et al., 1979;
Kohn, 1983). However, results obtained by Basu et al.
(1993), who noticed arrest of in Vitro replication of DNA in
the presence of mitomycin C monoadducts, suggest that also
monoadducts may be relevant for antitumor activity of
mitomycin C.
The unique mechanism of action of DNA cross-linking
by mitomycin C has inspired numerous efforts to design
synthetic analogs having the potential to undergo bioreduc-
tive activation to a bifunctional DNA alkylating agent. Most
of such analogs belong to the class of mitosenes, based on
the fact that mitosenes are intermediates in the reductive
activation path of mitomycin C (Scheme 1). Examples
include 1,10-functionalized mitosenes (Casner et al., 1985,
Verboom et al., 1987), cyclopropamitosenes (Jones &
Moody, 1989a,b; Cotterill et al., 1994), azamitosenes (PBI-
A) (Islam et al., 1991; Skibo & Schulz, 1993) the indolo-
quinone EO9 (Oostveen & Speckamp, 1987; Hendriks et al.,
1993) and nucleotide-mitosene conjugates (Iyengar et al.,
1988). Many of these have been shown to exhibit significant
antitumor activity. EO9 is currently under clinical trials
(Hendriks et al., 1993, Pavlidis et al., 1996).
Like mitomycin C, mitosenes can be activated reductively.
Chemical and enzymatic reduction of 7-methoxymitosenes
have been shown to result in loss of leaving groups at C-1
and/or C-10 (Maliepaard et al., 1993; Maliepaard, 1994).
Interestingly, upon reduction of 7-methoxymitosenes with
two acetoxy groups attached to the C-1 and C-10 site, the
acetoxy group at C-10 is expelled preferentially (Maliepaard
et al., 1993) (Scheme 3). In the presence of DNA, this
Scheme 1: Mechanism of Reductive Activation of the Electrophilic Centers C-1 and C-10 of Mitomycin C
Scheme 2: Adducts of Mitomycin C and DNA Formed by
Reductive Activation
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reductive activation of mitosenes has been shown to result
in the formation of DNA interstrand cross-links (Maliepaard
et al., 1993, 1994). The presence of two leaving groups
appears to be a prerequisite for in Vitro antitumor activity
of these mitosenes (Maliepaard et al., 1992), suggesting the
importance of interstrand DNA cross-links for this antitumor
activity.
Despite these advances, little has been known about the
actual DNA alkylation chemistry of these designed mito-
senes. No DNA adducts have been detected, isolated, and
characterized with any mitosene. Therefore, the intended
chemical analogy to the mono- and bifunctional alkylation
of DNA by mitomycin C (Scheme 1) and mitomycin A
(McGuinness et al., 1991) has remained conjectural for
mitosenes.
This investigation was aimed at demonstrating the forma-
tion of DNA adducts upon reductive activation of a synthetic
7-methoxymitosene WV15 (Verboom et al., 1987). This
compound shows promising activity in several in Vitro and
in ViVo tumor models (Orlemans et al., 1989). Herein, we
report the formation of several DNA adducts of this substance
in cell-free activation systems. The structure of the major
monoadducts was unambiguously determined, providing
evidence for the alkylation of DNA and its chemical
mechanism. The adduct structures revealed a difference
in the activation paths of the mitosene WV15 and mito-
mycin C.
MATERIALS AND METHODS
Mitosenes were synthesized as described previously (Or-
lemans et al., 1989) and were kept as 100 mM stock solutions
in N,N-dimethylformamide at 4 °C. The mitosenes used in
this study are shown in Table 1. All mitosenes possess a
chiral center at C-1 and have been used as racemic mixtures.
In addition, WV15 was resolved into its (+) and (-)
enantiomers, which were used separately in some experi-
ments. Calf thymus DNA (type I, sonicated before use),
Micrococcus lysodeikticus DNA (Micrococcus luteus DNA,
type XI, sonicated before use), NADH-cytochrome c reduc-
tase, and deoxynucleosides were purchased from Sigma (St.
Louis, MO). Snake venom diesterase (SVD,2 phosphodi-
esterase I, from Crotalus adamanteus) and Escherichia coli
alkaline phosphatase were from Worthington Biochemical
Corporation (Freehold, NJ). Nuclease P1, poly(deoxyad-
enosine-thymidine) [poly(dA-dT)] and poly(deoxyguanosine-
deoxycytidine) [poly(dG-dC)] were from Pharmacia Biotech
Inc. (Piscataway, NJ).
UV-vis measurements were performed on a Perkin-Elmer
ì 5 and a Cary 3 spectrophotometer, both connected to a
temperature controller. HPLC analyses were performed
using a 250  4.5 mm Beckman ODS C-18 Ultrasphere
reverse phase column. Products were eluted from the column
using a gradient of 13-40% (v/v) AcN/0.02 M NH4Ac in
20 min at a flow-rate of 1 mL/min and were detected using
a Beckman 165A detector at 254 nm. Peak areas were
quantitated with a Beckman 427M integrator. Preparative
HPLC was carried out using a Rainin HPLX instrument
equipped with a Dynamax C-18 column (21.4  250 mm)
and employing 16/84 AcN/H2O at 10 mL/min flow rate. 1H
NMR measurements in DMSO-d6 were performed at 400
MHz on a Varian Unity 400WB spectrometer. TOCSY
(MLEV17) (Bax & Davis, 1985) and DQF-COSY (Rance
et al., 1983) experiments were conducted using standard
Varian pulse programs. Mixing times of the TOCSY
experiments ranged from 40 to 120 ms. NMR data were
processed by the Varian VnmrS/VnmrX software packages.
Separation of Enantiomeric Forms of 1,10-Bis(acetoxy)-
mitosene WV15. Mitosene WV15 was separated into its two
enantiomeric forms using a 250  4.6 mm Chiralcel OD
column (Chiral Technologies Inc., Exton, PA). WV15 was
dissolved in 17/83 n-hexane/isopropyl alcohol (final con-
centration of WV15, 10 mM) by heating the solution at 50
°C for approximately 1 min. The enantiomers were eluted
with 70/30 n-hexane/isopropyl alcohol at a flow rate of 1
mL/min and were detected at 254 nm. The (+) and (-)
enantiomers of WV15 were collected separately. Finally,
the pooled (+) and (-) fractions were dried using a
rotavapor. Purity of the enantiomers was checked on the
Chiralcel OD column as well as on the Spherisorb S5-ODS2
C18 column and was estimated to be >98%. The absolute
configuration of (+) and (-) WV15 was determined using
circular dichroism (CD), as described later for mitosene-
Scheme 3: Mechanism of Sequential Reductive Activation of the Two Electrophilic Centers of WV15
Table 1: Structures of Mitosene Compounds (1)
compound X R1 R2
WV14 OCH3 -OH compound
WV15 OCH3 -OC(O)CH3 -OC(O)CH3
WV16 OCH3 -OC(O)N(H)C2H5 -OH
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DNA monoadducts 4 and 5. (+)-WV15 was assigned the
(R), and (-)-WV15 the (S) configuration at the C-1 position.
Preparation of Mitosene-DNA Complexes. (1) Chemical
Reduction. In a volume of 1 mL, 0.67 ímol of calf thymus
or M. lysodeikticus DNA was mixed with 0.75 ímol of
mitosene in 0.015 M phosphate buffer, pH 6.0. The reaction
mixture was purged with argon for 10 min, and subsequently
two 25 íL portions of 30 mM Na2S2O4 were added at t ) 0
and 15 min. The Na2S2O4 solution was prepared freshly in
argon-purged buffer. After 30 min of reduction, the solution
was purged with air, and the reaction mixture was chro-
matographed immediately on a 56 2.5 cm Sephadex G-100
column, using 0.02 M NH4HCO3 as eluent. The DNA
fraction, eluting in the void volume, was collected.
(2) Enzymatic Reduction. M. lysodeikticus DNA (0.67
ímol), 0.75 ímol of mitosene, and 1.5 units of NADH-
cytochrome c reductase was dissolved in 1 mL of 0.015 M
phosphate buffer, pH 6.0. The reaction mixture was purged
with argon for 10 min, and the reaction was started by adding
4.5 ímol of NADH. After 3 min of reduction, the reaction
mixture was flushed with air and immediately chromato-
graphed on a Sephadex G-100 column as described above.
(3) Electrochemical Reduction. Mitosenes were reduced
in an electrochemical cell, consisting of a mercury pool
working electrode, an Ag/AgCl reference electrode and a
platinum basket counter electrode. A potential of -510 mV
vs Ag/AgCl was used for reduction of the mitosenes. A
solution of 1.2 ímol of M. lysodeikticus DNA in 0.015 M
phosphate buffer, pH 6.0, was purged with nitrogen for 10
min. Subsequently, the solution was reduced at -510 mV
vs Ag/AgCl until the current through the solution was
constant (after approximately 10 min). The reduction was
stopped, and 2.0 ímol of mitosene was added. After purging
with nitrogen for another 2 min, the solution was reduced at
-510 mV for 30 min. The solution was chromatographed
on a Sephadex G-100 column as described above.
(4) H2/PtO2 ActiVation. M. lysodeikticusDNA (0.66 ímol)
of and 0.75 ímol of mitosene were mixed together with 90
íg of PtO2. The solution was deaerated as described above,
and hydrogenation was performed for 5 min, followed by
purging with argon for 5 min. Further handling was as
described above.
Digestion of Mitosene-DNA Complexes. After separation
of the mitosene-DNA complexes from unbound mitosene
on a Sephadex G-100 column, the mitosene-DNA com-
plexes were digested using the nuclease P1/SVD/alkaline
phosphatase system (Borowy-Borowski et al., 1990). First,
2 units of nuclease P1 was added to 4 OD260 of mitosene-
DNA complex in dilute acetic acid, pH 5.5 (1 mL), and the
reaction mixture was incubated at 55 °C for 2 h. Subse-
quently, the pH was adjusted to pH 8.2. Next, 0.9 mM
MgCl2 and 16 units of SVD were added, and the mixture
was incubated at 37 °C for 1 h. After adding 6.4 units of
alkaline phosphatase, the samples were incubated for another
2 h at 37 °C. The digested samples were analyzed on
reversed phase HPLC as described above.
Bulk Preparation of Mitosene-Deoxyguanosine Monoad-
ducts. Deoxyguanosine (dG, 670 mg, 2.47 mmol), 150 mg
of mitosene WV15 (0.40 mmol), and 48 mg of PtO2 (0.12
mg/ímol of WV15) were dissolved in 80 mL of 0.015 M
phosphate buffer pH 6.0. The mixture was heated at 40 °C
until all dG was dissolved. Next, the solution was purged
with He for 15 min, followed by H2 purging for 5.5 min.
After purging with He and air (both 5 min), the reaction
mixture was loaded in six fractions on a 5.0  56 cm
Sephadex G-25 column and eluted with 0.02 M NH4HCO3.
The fractions between 1890 and 2610 mL of the six
Sephadex G-25 chromatography runs were pooled and
concentrated on a rotavapor to a final volume of 35 mL.
This solution was stored at 4 °C until chromatographing it
on a preparative C-18 HPLC column.
1H NMR Measurements. After concentrating the pooled
fractions of the bulk preparation, the mixtures were injected
on preparative HPLC. Using an isocratic 16/84 AcN/H2O
system, adducts 4 and 5 eluted after approximately 75 and
85 min, respectively. The fractions were collected separately,
dried on rotavapor, dissolved again in 40% MeOH/H2O, and
the HPLC separation step was repeated. The total yield of
this bulk preparation of adducts 4 and 5 was 3.9 and 3.6
mg, respectively. From analysis of the purified samples on
HPLC the purity of the adducts was estimated to be >95%.
After drying, the samples were used for 1H NMR measure-
ments without further purification, using TOCSY and 1H
NMR spectroscopy.
Determination of CD spectra of 1,10-Bis(acetoxy)mitosene
WV15 Enantiomers and Adducts 4 and 5. CD spectra were
determined on a Jasco 720 spectropolarimeter. The solvent
used was methanol. The extinction coefficient of apomito-
mycin A (2) at 346 nm is 3620 (Webb et al., 1962b), and
the same value was used for adducts 4 and 5. Apomitomycin
A was prepared by acid hydrolysis of mitomycin A, as
described (Taylor & Remers, 1975).
RESULTS
Formation of Adducts of M. lysodeikticus DNA and
7-Methoxymitosene WV15 under Various ActiVating Condi-
tions. Mitosene-DNA complexes were prepared using
either Na2S2O4, NADH-cytochrome c reductase/NADH,
electrochemical reduction, or H2/PtO2 as reductive activating
agents. The complexes were digested to nucleosides and
mitosene-nucleoside adducts. The reaction products were
analyzed by HPLC. The HPLC pattern is shown in Figure
1. The unmodified deoxynucleosides are eluted early. Later-
eluting peaks, marked 3-7, correspond to putative adducts.
These were not detected in control experiments using WV15
without DNA or DNA without WV15. Several peaks, i.e.,
at t ) 9, 10, 14.5, and 20 min (marked with asterisks in
Figure 1), appeared to be present in the digest of control
samples, originally containing all components, except com-
pound WV15. Therefore, these peaks most likely are
products of DNA or digesting enzymes themselves. These
peaks were not detected in previously reported, similar
experiments using mitomycin C or mitomycin A (Tomasz
et al., 1987; McGuinness et al., 1991), probably due to a
more polar eluent used in those studies. Use of the four
different activating agents resulted in similar patterns, with
the notable exceptions of Na2S2O4, which failed to yield
adducts 6 and 7, and NADH-cytochrome c reductase, which
induced an additional component preceding adduct 6. This
product was not futher characterized.
As is evident from Figure 1, the relative amounts of
putative adducts 3-5 depend on the type of reduction. In
the case of Na2S2O4 reduction, relatively more of adduct 3
is formed, while using the other types of reduction, adducts
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4 and 5 are more abundant. However, the total amount of
adducts 3-5 that was formed upon Na2S2O4 reduction was
lower than that using the other types of reduction. This
reduced yield is likely to be caused by trapping of reduced
mitosenes by the dithionite nucleophile (Schiltz & Kohn,
1993a,b). Upon dialysis of the mitosene-DNA complexes
against 0.015 M phosphate/1 mM EDTA buffer, pH 7.4,
adducts 3-5 appeared to be more stable than adducts 6 and
7. Because of the abundance (except when using Na2S2O4
reduction) and the stability of adducts 4 and 5, we mainly
focused on these two adducts in further experiments.
Previously, DNA cross-linking by mitosenes following
chemical reduction has been shown to be pH dependent, with
enhanced DNA cross-linking at lower pH (Maliepaard et al.,
1993). However, no such pH dependence was observed for
the formation of adducts 3-5. Digestion and HPLC analysis
of WV15-DNA adduct preparations using Na2S2O4 reduc-
tion, performed at pH 7.4 and 6.0, yielded identical adduct
patterns. At both pH values, comparable amounts of these
adducts were formed (not shown).
Requirement of Reduction of the Mitosene for DNA Adduct
Formation. In order to study the importance of reduction
for DNA adduct formation by WV15, reactions were
performed without reduction of the mitosene, both at pH 6.0
and 7.4. These incubation mixtures were kept at 25 °C for
4 days, after which the DNA was separated from unreacted
mitosenes on a Sephadex G-100 column and subsequently
digested. HPLC analysis of the mitosene-containing frac-
tions from the Sephadex G-100 column showed the presence
of various reaction products of WV15. The two main
products found were 1-hydroxy-10-acetoxy-7-methoxymi-
tosene and 1,10-dihydroxy-7-methoxymitosene WV14. Also
some 1-acetoxy-10-hydroxy-7-methoxymitosene could be
detected (not shown). The relatively high amount of C-1
deacetylated product without reduction is in agreement with
previously reported observations (Maliepaard et al., 1993):
without reduction, loss of the acetoxy group was shown to
occur mainly at the C-1 site of WV15, whereas upon
reduction, the C-10 acetoxy group is more eager to react
(Scheme 3). Upon HPLC analysis of the digested DNA
fractions of these reactions, no DNA adduct peaks were
detected, thus demonstrating that in the case of WV15,
reduction is a prerequisite for adduct formation, both at pH
6.0 and 7.4.
Requirement of Good LeaVing Groups at C-1 and/or C-10
for DNA Adduct Formation. Earlier experiments showed
the necessity of good leaving groups for DNA cross-link
formation following reductive activation with Na2S2O4
(Maliepaard et al., 1994). Therefore, we used WV14, which
has two poor leaving OH groups at C-1 and C-10 to verify
the importance of leaving groups at C-1 and C-10 for the
formation of adducts 3-7. In these DNA alkylation experi-
ments, WV14 was reduced at pH 6.0 using Na2S2O4 or
NADH-cytochrome c reductase. No formation of adducts
3-7 was observed in chromatograms of the digestion
mixtures (not shown). In addition, the reaction has been
monitored without reduction at pH 6.0 and 7.4, analogously
as described above for WV15, and again these reactions did
not reveal any DNA adduct peaks.
Adducts Formed with Synthetic Polynucleotides. Ad-
ditional information concerning the identity of the adducts
3-7 was obtained from experiments using polynucleotides
instead of DNA in the adduct preparations. Both poly(dA-
dT) and poly(dC-dG) were used, and WV15 was activated
using the H2/PtO2 system or NADH-cytochrome c reductase
as described in Materials and Methods. Adducts 3-7 were
only present when poly(dC-dG) was used (not shown). From
this, it was concluded that the adducts that were detected in
the presence of DNA are likely to be mitosene-2′-deoxygua-
nosine adducts.
The Structures of Adducts 4 and 5. The UV spectra of
adducts 4 and 5 were identical (Figure 2a) and exhibited
characteristic mitosene absorption maxima at 235, 282, and
361 nm, together with the 2′-deoxyguanosine absorption
maximum at 256 nm. These spectra are very similar to the
UV-vis spectrum that was obtained from a 1:1 mixture of
1,10-dihydroxy-7-methoxymitosene WV14 and 2′-deoxygua-
nosine [Figure 2b, mitosene absorption maxima at 236, 278,
and 355 nm, 2′-deoxyguanosine absorption maximum (shoul-
der) at 253 nm]. UV-vis spectra of mixtures of WV14 with
FIGURE 1: HPLC profile, resulting from digestion of WV15-DNA
reaction mixtures following various ways of reduction. WV15
(0.075 ímol) was reductively activated in 0.015 M phosphate buffer,
pH 6.0, under anaerobic conditions. The following activation
methods were used: (a) 2-fold excess Na2S2O4; (b) 1.5 units of
NADH-cytochrome c reductase/4.5 ímol of NADH; (c) electro-
chemical reduction on a mercury pool working electrode at -510
mV vs Ag/AgCl; (d) H2/PtO2 activation (90 íg PtO2). Digestion
of the WV15-DNA mixtures was performed using nuclease P1/
SVD/alkaline phosphatase. Details are described in Materials and
Methods.
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other nucleosides yielded different UV-vis spectra (not
shown).
Attempts to characterize adducts 4 and 5 with EI and CI
mass spectrometry were not successful. However, conclusive
evidence for the involvement of 2′-deoxyguanosine in the
DNA adduct formation was obtained from positive ion
electrospray mass spectrometry. The mixture of adducts 4
and 5 yielded only one mass peak, at m/z ) 527.63. The
calculated mass of adduct 4 or 5 is 526.181 (C24H26N6O8).
The m/z value found corresponds to the [M + H+]of this
adduct. The relative stability of adducts 4 and 5 upon heating
indicated that these adducts are unlikely to be N7-2′-
deoxyguanosine adducts. After 30 min of heating at 100
°C in 0.015 M phosphate buffer, pH 7.4, only 12% of adducts
4 and 5 was destroyed, as measured from the peak areas on
the chromatograms (not shown). Under these heating
conditions, N7-2′-deoxyguanosine adducts are known to be
unstable, undergoing complete hydrolysis of the glycosidic
linkage (Lawley & Brookes, 1963).
Role of C-10 as the ActiVe Site for Forming Adducts 4
and 5. DNA was reacted with 1-hydroxy-10-ethylcarbam-
oylmitosene WV16 (Table 1). Due to the presence of a good
leaving group only at the C-10 site of this molecule, it was
expected to bind to DNA exclusively at that site upon
reductive activation. Analysis of the digestion mixture of
this reaction indeed revealed the presence of adducts 4 and
5, and this supports the hypothesis that binding to 2′-
deoxyguanosine in these adducts occurs via the mitosene
C-10 site. Moreover, the presence of both adducts 4 and 5
in the WV16/DNA digestion mixture suggested that the
double peak at 13.5 min (marked 4 and 5) represents two
stereoisomeric forms of the same adduct, due to the chiral
atom at C-1, common to both WV15 and WV16. This
possibility was verified as follows.
Diastereoisomeric Relationship between Adducts 4 and 5.
The two adducts have nearly mirror image CD spectra in
the 220-300 nm spectral region (Figure 3a). Interestingly,
their most intense Cotton effect, at 237 nm, coincides with
the most intense Cotton effect of the two enantiomeric forms
of the parent drug, (+)- and (-)-WV15 (positive at 235 nm
and negative at 237 nm, respectively; Figure 3b). This
suggested that monoadduct 4 (positive Cotton effect at 237
nm) and 5 (negative Cotton effect at 237 nm) were derived
from (+)- and (-)-WV15, respectively. This was experi-
mentally confirmed by comparing the HPLC patterns of
adducts obtained using either racemic (+)- or (-)-WV15 to
alkylate DNA (Figure 4). Using a single enantiomer resulted
in the elimination of two of the five adducts. The relation-
ship observed between a single WV15 enantiomer and its
resulting adduct 4 or 5 was the same as predicted from the
CD: (+)-WV15 gave 4 and (-)-WV15 gave 5. These
results strongly suggested that adducts 4 and 5 were
diastereoisomers. An analogous relationship was observed
for adducts 6 and 7, but adduct 3 was formed from either
WV15 enantiomers (Figure 4).
1H NMR of adducts 4 and 5 confirmed the above
conclusions. For the NMR analysis, the adducts were
prepared from deoxyguanosine on larger scale, as described
in Materials and Methods, in order to obtain sufficient
amounts of these adducts. The presence of adducts 4 and 5
in the Sephadex G-25 fractions between 1890 and 2610 mL
was demonstrated by HPLC coinjection with original samples
from the analytical scale pure preparations of 4 and 5 from
DNA and by comparison of UV-vis spectra. No compound
3, 6, or 7 was detected in these bulk preparation fractions.
The 1H NMR spectrum of adduct 5, and TOCSY spectra of
adducts 4 and 5 are shown in Figure 5. 1H NMR data of
the two adducts are summarized in Table 2.
In both 1H NMR spectra of adducts 4 and 5 the 2′-deoxy-
â-guanosine characteristics were present [see Wu¨thrich
(1990)]. Importantly, the C-8 proton signal of the guanosine
moiety was observed at 7.93 ppm. Therefore, binding of
the mitosene to the N-7 position of guanine can be excluded
for both adducts 4 and 5, since the C-8 proton of 7-alkylated
guanosines is shifted downfield to above 9 ppm (Hurd &
Reid, 1979). Moreover, in the TOCSY spectrum (see Figure
5), cross-peaks were detected between the guanine-N2 proton
signal (at 6.64 ppm for adduct 4, and at 6.68 ppm for adduct
5) and the mitosene 10′′-CHR and 10′′-CHâ signals (at 4.45/
4.66 ppm for adduct 4 and at 4.47/4.62 ppm for adduct 5).
This clearly indicates that the guanine moiety is bonded to
the mitosene via a -CH2-NH-bridge, and that bonding thus
occurs via the mitosene C-10′′ site. The chemical shifts and
coupling pattern of these protons are essentially identical to
the analogous protons in the mitomycin C cross-link adduct
(Tomasz et al., 1987), and to the 2,7-diaminomitosene-
FIGURE 2: UV-vis spectra, recorded in 0.015 M phosphate buffer
pH 7.4: (a) adduct 4 (s) and adduct 5 (---); (b) 1:1 mixture of
dihydroxymitosene WV14/2′-deoxyguanosine.
Table 2: Selected 1H NMR Data of Products 4 and 5
ä (ppm) in DMSO-d6






10′′-CH2NH 4.45, 4.66 4.47, 4.62
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deoxyguanosine adduct (Iyengar et al., 1990), which contain
the same C-10′′-guanine-N2 linkage. The C-1′′ site of both
adducts 4 and 5 appeared to be hydroxylated, with the 1′′-
proton signals of adducts 4 and 5 at 5.13 ppm. This value
for the 1′′-proton signal is close to the value obtained for
the C-1 deacetylated product of WV15 (5.26 ppm), as
characterized previously (Maliepaard et al., 1993). The 1′′-
OH proton signal was detected at 5.53 ppm for adduct 4
and at 5.61 ppm for adduct 5. From these results, adducts
4 and 5 were conclusively characterized as the diastereoi-
somers N2-(1′′-n-hydroxymitosen-10′′-yl), 2′-deoxyguanosine
(n ) R or â, Chart 2). However, the absolute configuration
of the C-1′′ hydroxyl groups in adduct 4 or 5 could not be
determined from these measurements.
In order to determine this absolute configuration, CD
measurements were performed. This technique has been
used successfully in the determination of the absolute
configuration of mitomycin C-DNA adducts (Tomasz et al.,
1984). The CD spectra of adducts 4 and 5 (Figure 3a) show
an approximate mirror image relationship, despite the fact
that 4 and 5 are diastereoisomers. This indicates that the
chirality of the C-1′′ stereocenter predominantly determines
the direction of the Cotton effects, although the deoxygua-
nosine moiety undoubtedly contributes to the overall shape
of the spectrum. An entirely analogous, quasi-mirror image
relationship of the CD exists between the C-1′′R- and C-1′′â-
deoxyguanosyl monoadducts of mitomycin C (Gargiulo et
al, 1995). In general, CD studies in the mitomycin C-type
mitosene series indicated that the presence and chirality of
FIGURE 3: CD-spectra: (a) adducts 4 (---) and 5 (___); (b) (+)-WV15 (___) and (-)-WV15 (---); (c) apomitomycin A (---) and adduct 4 (___).
Chart 2 a
a dR ) 2′-deoxyribos-1′-yl.
FIGURE 4: HPLC profiles of WV15-DNA digests. WV15 enanti-
omers were reductively activated using NADH-cytochrome c
reductase under anaerobic conditions. Digestion of the WV15-DNA
mixtures was performed using nuclease P1/SVD/alkaline phos-
phatase. (a) (+)-WV15-DNA digest; (b) (-)-WV15-DNA digest;
(c) racemic WV15-DNA digest; (d) racemic WV15-DNA digest,
following heating for 20 min at 100 °C. Details are described in
Materials and methods.
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a C-2 (same as C-2′′ in DNA adducts) substituent does not
influence the CD spectrum which, however, responds
sensitively to the chirality of the C-1 (C-1′′ in DNA adducts)
substituent (Tomasz et al., 1984). This is apparent in the
comparison of the present, 7-methoxy-mitosene C-1′′ enan-
tiomers 4 and 5 also. Deoxyguanosine alone has negligible
CD above 280 nm (not shown).
Apomitomycin A (Chart 1, 2) which has the same
mitosene chromophore as well as the same hydroxy sub-
stituent in the chiral C-1 position as 4 and 5 displays a
prominent positive Cotton effect at 289 nm (¢ ) 1.45,
Figure 3c). We find that this 289 nm Cotton effect of
apomitomycin A has the same sign and magnitude as that
of adduct 4 (290 nm, ¢ ) 1.20), while it is opposite to that
of adduct 5. On the basis of all these findings, we conclude
with confidence that adduct 4 has the same C-1 configuration
[(S); C-1′′â-OH] as apomitomycin A (Taylor & Remers,
1975) while adduct 5 has the (R), i.e., C-1′′R-OH configu-
ration.
Structure of Adducts 6 and 7. By using the separated
enantiomers of WV15, additional information concerning the
identity of adducts 6 and 7 was obtained. Experiments with
(+)- and (-)-WV15 demonstrated that only one of these two
adducts is formed when enantiomerically pure WV15 is used
(see Figure 4, panels a and b). Upon heating of the
mitosene-DNA complexes at 100 °C for 20 min, adducts 6
and 7 could no longer be detected (see Figure 4d). From
these results, two possible structures of adducts 6 and 7 can
be hypothesized: (a) heat labile deoxyguanosine-N-7 ad-
ducts, or (b) heat labile C-1′′ acetoxylated precursors of
FIGURE 5: 1H NMR spectrum of adduct 5, and TOCSY spectra of adducts 4 and 5 in DMSO-d6. TOCSY spectra are combined in one
figure. Right lower part, 4; left upper part, 5.
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adducts 4 and 5. The latter possibility is based on the fact
that heating of a solution of WV15 at 100 °C for 20 min in
0.015 M phosphate buffer, pH 7.4, results in complete loss
of acetyl groups (data not shown). However, we tentatively
favor deoxyguanosine-N-7 adduct structures for 6 and 7
(Chart 2) on theoretical grounds (see Discussion).
DISCUSSION
The results demonstrate that 1,10-bis(acetoxy)-7-meth-
oxymitosene WV15 is capable of alkylating DNA following
reductive activation and that monoadduct formation takes
place via the C-10 site of the mitosene which becomes linked
to the 2-amino group of a guanine. Since WV15 is a racemic
mixture due to the C-1 chiral center, its adduction to
deoxyguanosine in DNA resulted in two diastereoisomers 4
and 5. Monomeric deoxyguanosine is also alkylated by
WV15 to give the same adducts 4 and 5. In addition to the
two diastereoisomers of this guanine-N2 adduct three other
guanine-mitosene adducts were detected, 3, 6, and 7. Since
these were not formed with deoxyguanosine as substrate, we
could not obtain them in sufficient quantities to determine
their structures. It is likely that some of them correspond
to bis(guanine) adducts since reduced WV15 is known to
cross-link DNA (Maliepaard et al., 1993). However, since
adducts 6 and 7 are heat-labile, this rules out their being
bis(guanine-N2) adducts in analogy to the mitomycin C bis-
(guanine-N2) adduct (Scheme 2). The latter is stable to heat,
as guanine-N2 adducts are in general. Therefore, the
diastereoisomeric mitosene adducts 6 and 7 may be guanine-
N-7-substituted products which are heat-labile (Chart 2). As
precedent, the reduced mitomycin C metabolite 2,7-diami-
nomitosene was recently shown to alkylate DNA at guanine-
N7 (Suresh Kumar et al., 1996). The heat-stable adduct 3,
however, may correspond to a bis(guanine-N2) cross-link
adduct.
Isolation and elucidation of the structure of the WV15
monoadducts 4 and 5 now validates the design of WV15 as
bioreductive DNA-alkylating agent, which mimics the action
of the prototype mitomycin C. However, there is an
interesting difference: 4 and 5 are C-10-substituted monoad-
ducts, in contrast to the monoadduct of mitomycin C, which
is formed exclusively at the C-1 (aziridine) position (Tomasz
et al., 1988a). Clearly, the relative reactivity of the two
alkylating functions at C-1 and C-10 is reversed in WV15
compared to mitomycin C. This was also observed in model
reductive hydrolysis experiments (Maliepaard et al., 1993;
Scheme 3).
What may be the causes of this reversal? First, the C-1
acetoxy groups of WV15 are less reactive than the aziridine
of mitomycin C. In addition, there is substantial evidence
that in 7-methoxymitomycins (e.g., mitomycin A; Chart 1),
the C-10 position is more reactive than that in the 7-ami-
nomitomycin series (McGuinness et al., 1991; Subramanian
& Kohn, 1993). Comparison in the mitosene series is also
available. The C-10 carbamate group of various 7-aminomi-
tosenes was hydrolytically stable upon reduction (Sharma
& Tomasz, 1994; Suresh Kumar et al., 1996). In contrast,
the same group in 7-methoxymitosenes underwent rapid
hydrolysis at C-10 when reduced (Maliepaard et al., 1993).
These findings provide a rationale for formation of C-10-
linked monoadducts of the 7-methoxymitosene WV15, unlike
the C-1-linked monoadducts of mitomycin C.
Increased C-10 reactivity of 7-methoxymitosenes as
compared to 7-aminomitosenes may also explain the apparent
paradox that 2,7-diaminomitosene alkylates DNA to give
exclusively a deoxyguanosine-N-7 monoadduct (Suresh
Kumar et al., submitted; Prakash et al., 1993) while the
7-methoxymitosene WV15 yields a deoxyguanosine-N2
monoadduct in major proportion. We propose that this
difference reflects SN2-type reactivity of the C-10 center of
the 7-aminomitosene versus SN1-type reactivity of that of
the 7-methoxymitosene. It is well-known that relatively
weak, i.e., SN2-type, alkylators are selective for the strongest
nucleophile in DNA, i.e., deoxyguanosine-N-7, while the
more reactive, SN1-type, alkylators are able to react with the
less nucleophilic N2-atom of guanine, among others (Lawley,
1984). It is possible that the unknown, heat-labile adducts
of 7-methoxymitosene WV15, 6 and 7 are deoxyguanosine-
N-7 adducts. This would indicate a mixed SN1/SN2 reactivity
of WV15. Elucidation of the structures of these unknown
adducts of WV15 would be useful for substantiating the
proposed mechanism.
To summarize the results of the comparison between
adducts of 7-methoxy and 7-aminomitosenes, it appears that
the 7-substituent in the quinone ring influences both the
relative reactivity of the C-1 and C-10 alkylating centers and
the site of DNA alkylation by these mitomycin analogs. This
relationship is relevant for mitomycin analog drug design.
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